Emergent BioSolutions Inc.

EBS

US29089Q1058

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 27/06/2024 BST			5-day change	1st Jan Change
6.98 ^USD	+6.40%		+7.88%	+190.83%

06-20	Benchmark Adjusts Emergent Biosolutions Price Target to $8 From $5, Maintains Buy Rating	MT
05-02	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Barry Labinger Resigns as Executive Vice President and President of Emergent BioSolutions, Inc.'s Biosciences Division

January 04, 2016 at 09:51 pm

Emergent BioSolutions, Inc. announced that effective as of January 4, 2016, Barry Labinger, the former Executive Vice President and President of the company's biosciences division, resigned from the company.

Latest news about Emergent BioSolutions Inc.

Benchmark Adjusts Emergent Biosolutions Price Target to $8 From $5, Maintains Buy Rating	06-20	MT
Sector Update: Health Care Stocks Softer Late Afternoon	05-02	MT
Sector Update: Health Care	05-02	MT
Top Midday Gainers	05-02	MT
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected	05-02	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Earnings Deluge Continues	05-02	MT
Fed Decision Eases Investor Anxiety as US Futures Trend Higher in Thursday's Premarket	05-02	MT
Top Premarket Gainers	05-02	MT
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Posts Q1 EPS $0.59	05-01	MT
Transcript : Emergent BioSolutions Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q1 Revenue $300.4M, vs. Street Est of $224.5M	05-01	MT
Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024	05-01	CI
Emergent BioSolutions Inc. Provides Revenue Guidance for the Second Quarter of 2024	05-01	CI
Emergent BioSolutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Emergent BioSolutions to lay off about 300 employees	05-01	RE
Emergent BioSolutions to cut 300 jobs	05-01	RE
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position	05-01	CI
Emergent BioSolutions Inc. Enters into A Consent, Waiver and Seventh Amendment to the Amended and Restated Credit Agreement	04-30	CI
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	04-24	MT
Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	03-25	MT
Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	03-25	CI
Sector Update: Health Care Stocks Rise Late Afternoon	03-12	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	03-12	MT
Emergent BioSolutions Tumbles After S&P Global Credit Downgrade	03-12	MT
Emergent BioSolutions Shares Drop on S&P Downgrade	03-12	DJ

Chart Emergent BioSolutions Inc.

Duration

Period

More charts

Company Profile

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Sector

Pharmaceuticals

Calendar

24/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Emergent BioSolutions Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.56 USD

Average target price

8 USD

Spread / Average Target

+21.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EMERGENT BIOSOLUTIONS INC.	+190.83%	344M
ELI LILLY AND COMPANY	+55.95%	811B
NOVO NORDISK A/S	+43.62%	640B
JOHNSON & JOHNSON	-6.98%	353B
MERCK & CO., INC.	+19.08%	333B
ABBVIE INC.	+9.05%	302B
ASTRAZENECA PLC	+16.30%	246B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.47%	218B
AMGEN INC.	+8.91%	168B

Other Pharmaceuticals

Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Pharmaceuticals

Barry Labinger Resigns as Executive Vice President and President of Emergent BioSolutions, Inc.'s Biosciences Division

EPS Revisions